The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)Multiple System Atrophy, MSA
Interventions
DRUG

Aleeto

"Aleeto is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection."

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER